Alpha Wave, a global investment company, led a $95m Series B round in Human Immunology Biosciences, a clinical-stage biotechnology company, with participation from Viking Global, Arkin Bio Capital, Jeito Capital and ARCH Venture Partners. "These funds allow us to advance felzartamab, our clinically differentiated lead therapeutic candidate, through clinical readouts in multiple indications and preparation for registrational studies. We are encouraged by promising clinical data to date for felzartamab and its anti-CD38 cell depletion approach, and we look forward to new data, including Phase 2 results from an investigator-initiated trial for antibody-mediated rejection in kidney transplant patients," Travis Murdoch, Human Immunology Biosciences CEO.